Difference between revisions of "Team:BostonU"

Line 283: Line 283:
 
   <div class="fade-in-div"> <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/f/f2/T--BostonU--RedGrey.svg"></img></a>
 
   <div class="fade-in-div"> <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/f/f2/T--BostonU--RedGrey.svg"></img></a>
 
     <section id="fade-in-wrapper" class="link-slideup">
 
     <section id="fade-in-wrapper" class="link-slideup">
−
       <p class="body-type">We explore the use of de novo designed riboriboregulators known as <a href="#">toehold switches</a> to drive recombinase-based logic in <a href="#">cell-free TX-TL systems.</a> We anticipate applications in <a href="#">point-of-care diagnostic technologies</a> such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p>
+
       <p class="body-type">Our project combines the functionality of <a href="#">computational logic</a> - powered by <a href="#">toehold switch</a> driven <a href="#">recombinases</a> - with the efficiency and simplicity of the <a href="#">Cell-Free transcription translation system</a> to detect RNA and produce an <a href="#">input specific response</a>. We anticipate applications in <a href="#">point-of-care diagnostic technologies</a> such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer. Now we understand that description is rather dense, but click on the links to learn more about each section of our project.</p>
 
     </section>
 
     </section>
 
     <div id="fade-in-footer">
 
     <div id="fade-in-footer">

Revision as of 21:39, 31 October 2017

Something is wrong! The description didn't load properly.